A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza VaccinesNeal Van Hoeven, Darrick Carter, Sarah Evans et al.|Scientific Reports|2017Cited by 86
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B. Fox, Steven G. Reed, Mark T. Orr et al.|Journal of Controlled Release|2016Cited by 65
A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsNeal Van Hoeven, Rhea N. Coler, Sharvari Waghmare Joshi et al.|PLoS ONE|2016Cited by 33